Raytheon awarded $71 million in Navy contracts for missile systems
Maria Palasis, President and CEO of Lyra Therapeutics, Inc. (NASDAQ:LYRA), sold 1565 shares of common stock on July 10, 2025, at a price of $8.91, for a total of $13944. The transaction occurred as the stock trades near $8.71, down roughly 43% over the past year. According to InvestingPro analysis, the company currently appears undervalued relative to its Fair Value.
Following the transaction, Palasis directly owns 1098435 shares of Lyra Therapeutics.
The sale was executed to cover taxes upon the vesting of restricted stock units, according to a pre-arranged Rule 10b5-1 trading plan adopted on January 1, 2025.
In other recent news, Lyra Therapeutics has reported significant developments that may interest investors. The company announced positive results from its Phase 3 ENLIGHTEN-2 trial for LYR-210, a treatment for chronic rhinosinusitis, which met its primary and key secondary endpoints. This achievement contrasts with the earlier ENLIGHTEN-1 trial, which did not succeed. Following these results, H.C. Wainwright raised its price target for Lyra Therapeutics to $16, maintaining a Neutral rating. Meanwhile, Lyra has regained compliance with Nasdaq’s minimum bid price requirement, as confirmed by a recent SEC filing. The company also secured approximately $5 million through a registered direct offering of common stock and warrants. Lyra intends to use these funds for working capital and other corporate purposes, including the development and potential commercialization of LYR-210. The company is planning to engage with the FDA to discuss a New Drug Application for patients without nasal polyps. As these developments unfold, investors are keenly observing the company’s strategic moves and regulatory interactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.